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https://doi.org/10.1016/j.jacl.2018.05.0BACKGROUND: Atherosclerosis starts in childhood and its progression is influenced by lifelong
low-density lipoprotein cholesterol (LDL-c) exposure, the so-called cholesterol burden. Early identifi-
cation of children and adolescents with severely elevated LDL-c is thus of major clinical significance.
This is especially true for children with familial hypercholesterolemia (FH), a frequent but undertreated
genetic disorder. To identify children with possible FH, insight in the distribution of lipid levels in chil-
dren is a prerequisite.
OBJECTIVE: To provide health care professionals with contemporary age- and gender-based pedi-
atric reference values for lipid and lipoprotein levels to help the identification of children with dysli-
pidemia, especially FH.
METHODS: Lifelines is a large prospective population-based Dutch cohort study. Children from 8
till 18 years of age were included and fasting lipid levels were measured. Smoothed reference curves
and percentiles (5th, 10th, 25th, 50th, 75th, 90th, and 95th) were generated using the Generalized Additive
Models for Location, Scale and Shape package in the statistical software R.
RESULTS: A total of 8071 children (3823 boys and 4248 girls) were included. In the total cohort we
noted marked dynamic changes in lipid and lipoprotein levels over age, which were in part gender spe-
cific. Our data highlight a high and unexpected prevalence of severely elevated LDL-c (.190 mg/dL)
in both boys and girls.
CONCLUSION: Our cross-sectional data provide contemporary reference ranges for plasma lipids
that can assist physicians in identifying children at increased risk of premature atherosclerosis, espe-
cially FH.
 2018 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).t of Pediatrics, Section Molecular
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11Introduction
Cardiovascular disease (CVD) represents a leading
cause of death globally.1 Most often men and women above
55 and 65 years of age, respectively, are affected, but fatty
streaks start developing at a very young age and thehis is an open access article under the CC BY-NC-ND license (http://
Balder et al Pediatric lipid reference ranges 1209progression of atherosclerosis is positively associated with
plasma low-density lipoprotein cholesterol (LDL-c) expo-
sure.2–4 This progression is accelerated in individuals
with familial hypercholesterolemia (FH), a genetic disorder
characterized by elevated LDL-c levels and premature
CVD. Mutations in LDLR, APOB, and PCSK9 have been
shown to cause FH. The prevalence of FH is estimated to
be 1 per 200 to 250 individuals but this lipid disorder is
severely underdiagnosed and undertreated.2,3 In children
with genetically confirmed FH, undertreatment is common
as well.5,6 Carriers of FH mutations suffer from increased
cardiovascular risk, related to a lifelong exposure to
increased LDL-c levels.7 In adults, and to a lesser extent
in children, identification of FH affected individuals is diffi-
cult because of the overlap of LDL-c levels in both FH and
non-FH individuals.8,9 In this context, genetic testing can
help in the clinical diagnosis of FH and in the screening
of affected family members, known as cascade
screening.10,11
Childhood is the best period to discriminate between
mutation-positive and mutation-negative hypercholesterole-
mia on the basis of plasma LDL-c levels only.9 Children with
LDL-c levels twice .190 mg/dL should be considered as
having FH, whereas 2 consecutive LDL-c levels .160 mg/
dL in combination with a family history of hypercholester-
olemia or premature CVD are highly suggestive of FH.
Finally, children of affected parent(s) with an LDL-c
.130 mg/dL are likely to have inherited the mutation.2
Initiation of statin treatment early in life (around 8 years)
is an accepted strategy in clinical practice,2,12,13 which
makes early identification of children with FH clinically
relevant.14 To date’s reference ranges are, however, based
on old or small-case studies.15–21
To provide such reference ranges, we used data of
Lifelines, a prospective population-based cohort study,
which was initiated in 2006.22,23 Using the same cohort,
we recently reported that lipid levels in adults are
strongly age- and gender-dependent, whereas the data
of participants below the age of 18 years were not yet
released.24 For the present study, we have generated
age- and gender-based reference values for lipid levels
in children, aged 8 till 18 years. These data can help
the identification of children at increased risk of athero-
sclerosis such as children with FH and assist cascade
screening in families.2Methods
Study population
The study protocol was approved by the Medical Ethical
Committee of the University Medical Center Groningen in
the Netherlands, and all participants provided written
informed consent. The rationale and design of Lifelines
have been described previously.22,23 In short, Lifelines is an
ongoing prospective population-based cohort study.Between 2006 and 2013 inhabitants from the 3 northern
provinces of the Netherlands (Groningen, Friesland, and
Drenthe) between 25 and 50 years of age were approached
by their general practitioner to participate. On a positive
response, relatives (first-degree family members, including
children [$6 months], partner, and parents-in-law) were
also invited. Individuals could also participate through
self-registration. Of the 167,729 almost exclusively Cauca-
sian participants, 14,801 are children. This multiple-
generation design offers the unique opportunity to study
the origins of multifactorial diseases. In total, 85,000
(51%) participants are part of a 2-generation family and
20,000 (12%) of a 3-generation family.
For the present study, we provide cross-sectional pop-
ulation distributions of plasma lipid levels of children
screened at the baseline visit. Of the total 14,801 children,
6730 were excluded because of (1) age ,8 years
(n 5 5137), because blood sampling was only performed
in children aged $8 years; (2) nonfasting (defined as an
overnight fast) lipid measurements (n 5 490); and (3)
missing lipids measurements (n 5 1103). In total, 8071
children (3823 boys and 4248 girls) were included.
Supplementary Table 1 provides the number of children
included for each year of age.
Questionnaires, physical examination, and
biomaterial collection
The parents of the children received questionnaires
specifically suited for the child’s age. The questionnaires
covered topics on lifestyle, health, nutrition, and develop-
ment. A physical examination was performed including
anthropometry, blood pressure measurement (10 measure-
ments during 10 minutes using Dinamap registration), and
pulmonary function tests. Fasting blood samples were
drawn after an overnight fast. Fresh samples were trans-
ferred to the central laboratory of University Medical
Center Groningen for routine clinical chemistry.
Cholesterol measurements
Total cholesterol, LDL-c, high-density lipoprotein
cholesterol (HDL-c), and triglycerides were directly
measured and were standardized against appropriate con-
trols as described.24 LDL-c levels were also calculated us-
ing the Friedewald formula,25 but only when triglyceride
levels did not exceed 400 mg/dL.
Statistics
Baseline characteristics that follow a normal distribution
were reported as mean and standard deviation. Baseline
characteristics with a skewed distribution were reported as
median and interquartile range.
Smoothed reference curves were generated using Gener-
alized Additive Models for Location, Scale and Shape.26
Let Y(t) be an outcome variable at age t. We used the
1210 Journal of Clinical Lipidology, Vol 12, No 5, October 2018Box-Cox-t power transformation with parameters m(t), s(t),





















The transformed variable Z(t) then follows a student
t-distribution with t(t) degrees of freedom. The relations
between the age t and all 4 parameters were modeled
with P-splines functions.
To compare our results to previously reported age- and
gender-based percentiles, we also calculated age- and
gender-based specific percentiles with corresponding age
groups. All analyses were performed stratified by sex and
carried out using IBM SPSS Statistics, version 22.0
(Armonk, NY: IBM Corp.) or the statistical software R
(version 3.2.2).Results
Study population
As clarified in the methods section, a total of 8071
children were included in our study. Demographic and
clinical characteristics of the study population are shown in
Table 1. Mean age was, for both boys and girls, 12 years.
Furthermore, Table 1 shows that boys and girls have on
average similar lipid profiles, blood pressure, and glucose
levels. Supplementary Table 1 shows the number of
included children per year of age.Table 1 Demographics and clinical characteristics
Characteristics
Boys Girls
(n 5 3823) (n 5 4248)
Age (y) 12 6 2.7 12 6 2.8
Lipid profile (mg/dL)
Total cholesterol 155 6 27 162 6 27
LDL-c 89 6 23 93 6 23
HDL-c 58 6 12 62 6 12
Triglycerides 52 (40–71) 62 (47–82)
SBP (mm Hg) 107 6 11 106 6 11
DBP (mm Hg) 59 6 6 60 6 6
Glucose (mmol/L) 4.7 6 0.5 4.6 6 0.5
HbA1c (%) 5.4 (3.0) 5.4 (0.3)
DBP, diastolic blood pressure; HDL-c, high-density lipoprotein
cholesterol; LDL-c, low-density lipoprotein cholesterol; SBP, systolic
blood pressure.
Data are expressed as mean 6 standard deviation but triglycerides
as interquartile range.The associations between age and fasting lipid param-
eters are depicted in Figure 1 for boys and girls separately,
using the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles.
Supplementary Table 2 shows age- and gender-specific
lipid percentiles, including the 5th, 10th, 50th, 90th, and
95th percentiles. In the following sections, we briefly
describe the main finding for different components of the
lipid profile.
Age, gender, and LDL-c levels
Boys aged 8 years presented with a median LDL-c of
89 mg/dL (95th percentile: 125 mg/dL). Over the age range
studied, LDL-c dropped in boys starting at approximately
12 years of age, with the lowest values around 15 years
of age. Interestingly, at ages 17 and 18 years, LDL-c ap-
pears to increase marginally.
In girls, LDL-c levels appeared to be slightly higher
compared with boys. As in the boys, a drop in LDL-c was
noted starting at 10 years of age, with the lowest values
around 14 years of age, thus a little earlier than in boys.
The increase in LDL-c at later ages (15.0–17.9) was more
pronounced in girls than boys. This is clearly illustrated at
17 years of age, when LDL-c is substantially higher
in girls compared with boys for both median (95 mg/dL
vs 82 mg/dL) and the 95th percentile (144 mg/dL vs
126 mg/dL).
In clinical practice, LDL-c levels are often calculated
using the Friedewald formula (f-LDL-c).25 Supplementary
Figure 1 shows the absolute difference between f-LDL-c
and direct measurement of LDL-c. Negative values
indicate lower f-LDL-c in comparison with direct mea-
surement of LDL-c and vice versa for positive values.
Supplementary Figure 1 indicates that the population
distribution of f-LDL-c is slightly lower in both
boys and girls. Overall, f-LDL-c was approximately
6 mg/dL lower as compared with direct measurement of
LDL-c. Clearly, with increasing triglyceride levels, the
discrepancy between direct measurement and f-LDL-c
increases.
Age, gender, and HDL-c levels
At 8 years of age, HDL-c levels are very similar in boys
and girls; however, our cross-sectional data show markedly
different HDL-c dynamics between genders with aging.
HDL-c increases in boys aged 8.0 to 10.9 years followed by
a strong decrease between ages 11.0 and 14.9 years, and a
subsequent stabilization. In girls, by contrast, HDL-c is
generally slowly decreasing with age.
Age, gender, and triglyceride levels
At 8 years of age, triglyceride levels are lower in boys
(median: 45 mg/dL; 95th percentile: 96 mg/dL) than in girls
(median: 52 mg/dL; 95th percentile: 105 mg/dL). In both
boys and girls, triglycerides levels increase with age over
Figure 1 Relation between age, gender, and lipid parameters. Age- and gender-based smoothed percentile curves (5th, 10th, 25th, 50th,
75th, 90th, and 95th) for total cholesterol, LDL-c, HDL-c, and triglycerides for boys and girls separately. LDL-c, low-density lipoprotein
cholesterol; HDL-c, high-density lipoprotein cholesterol.
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Figure 1 (continued).
1212 Journal of Clinical Lipidology, Vol 12, No 5, October 2018all percentiles studied. At the age of 18 years, median tri-
glycerides were 47% higher in boys and 46% higher in girls
compared with the boys and girls aged 8 years.
Extremes
In our study population, a considerable number of
children presented with severe hypercholesterolemia: 375
(4.6%) children presented with LDL-c levels .130 mg/dL.
Eighty (1.0%) children showed LDL-c .160 mg/dL, which
is a strong indicator of having FH. Eighteen children
(0.22%) presented with LDL-c levels .190 mg/dL and
could be considered as having FH (Table 2).
Discussion
This study provides tables with age- and gender-based
percentiles for lipid and lipoprotein levels in children and
adolescents, which can aid clinicians in the diagnosis of
dyslipidemia, and in their decisions if additional diag-
nostic evaluations are indicated. This will allow to
distinguish severe dyslipidemia, where pharmacological






Total cholesterol . 200 mg/dL 412 (5.1%)
LDL-c . 130 mg/dL 375 (4.6%)
LDL-c . 160 mg/dL 80 (1.0%)
LDL-c . 190 mg/dL 18 (0.22%)
HDL-c , 40 mg/dL 362 (4.5%)
Triglycerides . 133 mg/dL 282 (3.5%) 1
HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoproteinneed of lifestyle advice. We believe that the presented
reference ranges are a prerequisite for effective screening
and identification of children and adolescents with FH. In
our study population (children and adolescents of Cauca-
sian descent), we identified a prevalence of 1:450 for FH
(LDL-C . 190 mg/dL).
Importance of lipid reference values in clinical
practice
Several studies have shown that young children with
increased total cholesterol levels, for example above the
90th percentile, will maintain their percentile ranking over
time.29,30 This is why timely identification and treatment
of children and adolescents with severely elevated choles-
terol levels, can be an important step in reducing cardio-
vascular events. The recommended diet of children with
FH should include less consumption of total fat (,30%
of calories), saturated fat (,7% of calories), and less
than 200 mg of cholesterol/d. Furthermore, the consump-
tion of heart-healthy foods such as fruit, vegetables, and
whole grain should be encouraged.2 Besides diet interven-














Figure 2 Comparison between lipid parameters between Lifelines and the LRC Prevalence study. Comparison of total cholesterol,
LDL-c, HDL-c, and triglycerides between Lifelines (dotted line) and LRC Prevalence study (solid line). The lines correspond to the
5th, median and 95th percentile. LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol.
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Figure 2 (continued).
1214 Journal of Clinical Lipidology, Vol 12, No 5, October 2018statins combined with cholesterol absorption inhibitors are
fundamental to FH management.31 Current guidelines
advocate initiating statin treatment in children with FH
from the age of 8 years onward.2,13 Although long-term
data on safety and cardiovascular outcomes for statin
treated children are limited, follow-up studies showed
normalization of progression of carotid intima-media
thickness in statin-treated FH children.31,32 Importantly,
side-effects have been reported to be rare.33,34
Screening for FH is a worldwide challenge. The most
commonly used diagnostic criteria for FH (ie, Dutch Lipid
Clinic Network and Simon Broome criteria) are however
not applicable to children. Currently, 2 times plasma LDL-c
levels .190 mg/dL is used as diagnostic criterion, whereas
a threshold of 130 mg/dL is used in case of affected family
members.2 Universal pediatric screening of FH (phenotype-
based screening) could be effectively incorporated in infant
health checkups such as immunization programs.35 This
has been proven to be a highly effective approach,
especially if reverse cascade screening to identify
affected family members is integrated (genotype-based
screening).9,36–38 Age-specific diagnostic LDL-c cutoff
criteria for diagnosis of relatives with FH have been
published previously.39
In line with other cross-sectional studies, we show that
lipid distributions change with age.17,18,40,41 When studying
adolescents around 11–16 year of age with a pronounced
fall in cholesterol levels (see Fig. 1), the use of a fixed
LDL-c level for a diagnosis of FH can easily result in a
misdiagnosis. In case of a clinical suspicion of FH because
of, for example, familial presence of hypercholesterolemia
or premature CVD, genetic testing can also provide a better
tool for diagnosis. Finally, using age- and gender-specific
LDL-c cutoff values can also help to identify subjects
with FH as we recently showed in young premenopausal
women.42Comparison with the LRC prevalence study
The LRC Prevalence study, conducted in the United
States in 1970s,40 has provided clinicians and researchers
with cross-sectional lipid reference values.43 Because of
differences in lifestyle, cholesterol analysis methods,
time of inclusion (w30 year difference), and ethnicity,
dissimilarities in the distribution of lipid parameters
were anticipated. After matching age groups, we
compared the age- and gender-based percentiles from
LRC Prevalence study with the Lifelines study (Fig. 2).
LDL-c levels were lower in boys (w8 mg/dL) of the Life-
lines cohort during adolescence while this discrepancy
was not observed in girls. HDL-c levels were higher in
both boys and girls in Lifelines compared with the LRC
study, whereas triglycerides were slightly lower. The US
National Health and Nutrition Examination Surveys previ-
ously showed an initial decline of total cholesterol levels
in children and young adults (aged 4–19 years) between
1966 and 1970 and 1988 and 1994.15 The detrimental in-
crease in overweight and obesity in children over the past
decades,44 which is associated with dyslipidemia,28 may
have reversed the initial lowering of LDL-c levels
observed at that time.
Frequency of pediatric hypercholesterolemia
In our study population, 4.6% of the children presented
with LDL-c levels .130 mg/dL. In the United States19,21
and Germany,18 higher percentages were reported, 7.0%
and 6.1%, respectively (Table 2). It is possible that the
lower frequency of hypercholesterolemia in our cohort is
related to the use of lipid-lowering drugs, but we cannot
verify this as Lifelines pediatrics questionnaires do not
cover medication use. By contrast, in a pediatric Brazilian
cohort (age 12–17 year),45 the prevalence of LDL-c
Balder et al Pediatric lipid reference ranges 1215.190 mg/dL was lower compared with Lifelines, but this
could also be a consequence of declining LDL-c levels in
adolescence. It may be noted that statements about fre-
quencies of FH in our population are hampered by 1 time
point measurements, instead of recommended repeated
measurements.
Strengths and limitations
The strengths of our study are the large number of
children included and that the measurement of lipid levels
was performed on fresh samples in a single central
laboratory. We cannot ensure that our study population is
representative of the Dutch pediatric population. The adult
Lifelines study cohort has, however, been described to be
slightly healthier compared with the larger Dutch popula-
tion,22 and it is thus likely that our pediatric cohort popula-
tion is also healthier. Another limitation is that almost all
Lifelines participants are of Caucasian descent, and there-
fore, our reference ranges may be not applicable to other
ethnicities. We could not asses the relationship between pu-
bertal stage and lipid levels as the Tanner stages of pubertal
development have not been evaluated in the Lifelines
cohort.
Conclusions
Our study provides contemporary age- and gender-based
reference values for plasma lipid and lipoprotein levels in
children and adolescents. We expect that these lipid and
lipoprotein values, translated into age- and gender-specific
percentiles, can serve clinicians as an effective and reliable
instrument to help identifying children and adolescents
with dyslipidemia, especially FH.Acknowledgments
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